Division of Respirology, Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.
Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.
Br J Clin Pharmacol. 2018 Mar;84(3):579-589. doi: 10.1111/bcp.13465. Epub 2017 Dec 6.
Diuretic drugs may theoretically improve respiratory health outcomes in chronic obstructive pulmonary disease (COPD) through several possible mechanisms, but they might also lead to respiratory harm. We evaluated the association of incident oral diuretic drug use with respiratory-related morbidity and mortality among older adults with COPD.
This was a population-based, retrospective cohort study using health administrative data from Ontario, Canada, for the period 2008-2013. We identified adults aged 66 years and older with nonpalliative COPD using a validated algorithm. Respiratory-related morbidity and mortality were evaluated within 30 days of incident oral diuretic drug use compared to nonuse using Cox proportional hazard regression and applying inverse probability of treatment weighting using the propensity score to minimize confounding.
Out of 99 766 individuals aged 66 years and older with COPD identified, incident diuretic receipt occurred in 51.7%. Relative to controls, incident diuretic users had significantly increased rates for hospitalization for COPD or pneumonia [hazard ratio (HR) 1.22, 95% confidence interval (CI) 1.07-1.40], as well as more emergency room visits for COPD or pneumonia (HR 1.35, 95% CI 1.18-1.56), COPD or pneumonia-related mortality (HR 1.41; 95% CI 1.04-1.92) and all-cause mortality (HR 1.20, 95% CI 1.06-1.35). The increased respiratory-related morbidity and mortality observed were specifically as a result of loop diuretic use.
Incident diuretic drugs, and more specifically loop diuretics, were associated with increased rates of respiratory-related morbidity and mortality among older adults with nonpalliative COPD. Further studies are needed to determine if this association is causative or due to unresolved confounding.
利尿剂药物通过几种可能的机制理论上可以改善慢性阻塞性肺疾病(COPD)的呼吸健康结果,但也可能导致呼吸损害。我们评估了老年 COPD 患者中使用利尿剂与呼吸相关发病率和死亡率的关系。
这是一项基于人群的回顾性队列研究,使用来自加拿大安大略省的健康管理数据,时间范围为 2008-2013 年。我们使用经过验证的算法确定患有非姑息性 COPD 的 66 岁及以上成年人。使用 Cox 比例风险回归评估与非使用相比,在使用口服利尿剂后 30 天内与呼吸相关的发病率和死亡率,并用倾向评分进行逆概率治疗加权以最小化混杂。
在确定的 99766 名 66 岁及以上患有 COPD 的患者中,有 51.7%的患者使用了利尿剂。与对照组相比,使用利尿剂的患者因 COPD 或肺炎住院的比例显著增加[风险比(HR)1.22,95%置信区间(CI)1.07-1.40],因 COPD 或肺炎就诊的急诊次数也有所增加(HR 1.35,95% CI 1.18-1.56),COPD 或肺炎相关死亡率(HR 1.41;95% CI 1.04-1.92)和全因死亡率(HR 1.20,95% CI 1.06-1.35)。观察到的呼吸相关发病率和死亡率的增加是由于使用了袢利尿剂。
在患有非姑息性 COPD 的老年患者中,利尿剂药物的使用,更具体地说是袢利尿剂,与呼吸相关发病率和死亡率的增加有关。需要进一步的研究来确定这种关联是因果关系还是由于未解决的混杂因素所致。